Altevir 3000000ME 1ml #5

Instruction for Altevir

Reed more and buy Altevir here

Composition

The solution contains human recombinant interferon alpha-2b as an active component, as well as additional components such as sodium acetate, ethylenediaminetetraacetic acid disodium salt, dextran 40, sodium chloride, purified water for injection, Tween 80.

Form of issue

The drug is in the form of a solution for injection.

pharmachologic effect

The drug has antiviral, antiproliferative, immunomodulating and antitumor properties.

Pharmacodynamics and pharmacokinetics

The active substance of the drug interacts with receptors on the surface of cells, initiating a complex chain of transformations (for example, induction of the synthesis of cytokines and enzymes), and also interferes with the synthesis of viral RNA and proteins of the virus. This causes the antiviral and antiproliferative effect of the drug.
In addition, the active substance Altevir activates the presentation of the antigen to immunocompetent cells. It also stimulates the cytotoxic effect of T cells and the phagocytic activity of macrophages, inhibits the synthesis of certain oncogenes and inhibits the proliferation of cells, including tumor cells.
Bioavailability of the drug is about 90%. The elimination half-life is 2-6 hours. The drug is excreted through the kidneys through glomerular filtration. After 16-24 hours the active substance in the blood is not detected. It is split in the liver.

Indications for use

The drug is used for:
    hairy cell leukemia;
    chronic viral hepatitis B (if there is no cirrhosis of the liver and its signs);
    non-Hodgkin's lymphoma;
    papillomatosis of the larynx;
    multiple myeloma;
    genital warts;
    progressive kidney cancer;
    chronic viral hepatitis C (if there is no hepatic insufficiency and its signs) - ribavirin joins the complex therapy;
    chronic myelogenous leukemia;
    melanoma;
    sarcoma Kaposi in AIDS.

Contraindications

Altevir does not apply when:
    hypersensitivity to the components of the drug;
    severe renal failure;
    chronic hepatitis with decompensated hepatic cirrhosis;
    reception immunodepressive drugs;
    decompensated lung disease;
    hypercoagulation;
    severe hepatic insufficiency;
    pregnancy;
    lactation;
    severe cardiovascular diseases;
    severe disorders in the central nervous system (especially in the case of epilepsy, depression);
    autoimmune diseases;
    decompensated diabetes mellitus;
    pronounced myelosuppression.

Side effects of Altevir

Side effects of Altevir are most often manifested in the form of fever, headache, chills, nausea, general weakness, myalgia, blunting appetite.
In addition, vomiting, arthralgia, drowsiness, dry mouth, depression, malaise, taste change, insomnia, diarrhea, suicidal attempts, asthenia, dizziness, alopecia, increased sweating, irritability, lowering of blood pressure are possible.
In rare cases, there are pains in the abdomen, nervousness, anxiety, dyspepsia, autoimmune thyroiditis. There may be changes in laboratory indicators (reversible): leukopenia, a decrease in the level of hemoglobin, increased activity of liver enzymes, granulocytopenia, thrombocytopenia.

Instructions for Altevir

The drug is administered intramuscularly, intravenously, intraperitoneally, subcutaneously, intrathecally, into the lesion focus. The instruction for Altevir provides the following single dose for adults - 3-6 million IU. If necessary, it can go up. Children are assigned 500-100 thousand IU per kilogram of weight.
Depending on the disease, the instructions for use also provide for the following admission schemes:
    papillomatosis of the larynx - adults 6 million IU 5 times in 7 days or 3-6 million IU three times in 7 days (treatment course - a month), 3 million IU twice in 7 days (treatment course - 12 weeks), 3 million IU times in 7 days (course of treatment - 28 weeks); children 50-100 thousand IU three times in 7 days (course of treatment - a month), 50 thousand IU every 7 days (course of treatment - 28 weeks), 50 thousand IU twice for 7 days (course of treatment - 12 weeks ). In the case of disease progression, the dosage may be increased;
    severe hepatic insufficiency in infants - 3-6 million IU / sq. m the doctor appoints intraperitoneally throughout the week, should be used daily. During the second week of treatment, the same dosage is administered intramuscularly. Frequency of reception can be reduced up to 3 times a week from the third week;
    chronic hepatitis B - specialists for adult patients recommend taking 6 million IU intramuscularly for two weeks each day, then twice in 7 days (course of treatment - 16 weeks) and three times in 7 days (treatment course - a month); children under 12 years should take 3-6 million IU / square meter intramuscularly three times in 7 days (treatment course - 16 weeks); children aged 12 years take a single dose of 6 million IU;
    chronic hepatitis C - experts point out that adults 3 million IU in the form of subcutaneous or intramuscular injections 3 times per 7 days (treatment course - 9 months), children need to take 3 million IU / sq.m according to the same scheme;
    HIV infection - you need to take 3 million IU three times in 7 days. If neutralizing antibodies appear, the drug is replaced with natural interferon;
    Dengue fever - taken within 72 hours after the onset of symptoms, adults are prescribed to take 3-6 million IU 3 days daily, children take 50-100 thousand IU per kilogram of weight according to the same scheme;
    non-Hodgkin's lymphoma (malignancy medium or low) - the drug is taken after remission, which is achieved through polychemotherapy. It should be administered 6 million IU three times in 7 days;
    genital warts - adult patients should be given 6 million IU (the entire course of treatment is designed for 6 weeks) daily in combination with interferon alpha2b (ointment) three times every day, patients in childhood are assigned 50-100 thousand IU per kilogram;
    viral hepatitis - first 12-15 million IU (it should be used 3-5 days) intramuscularly or intraperitoneally every day, then 6 million IU in the form of intramuscular injections every other day until negative results are known regarding viral hepatitis markers; in the case of subacute viral hepatitis in childhood after 1 year, take 3-6 million IU / sq. m 1-2 weeks (the first week intraperitoneally, then intramuscularly), then the treatment can be continued with the same dosage, but three times in 7 days before the achievement of negative indicators on the markers of the disease;
    Kaposi's sarcoma - appoint 30 million IU for daily intake, with early diagnosis - 6 million IU (apply should be 6 weeks) daily, the same dosage is prescribed for children;
    chronic myelogenous leukemia - after hematologic remission take 3 million IU / sq. m. a day before cytogenetic remission or regression of the disease;
    Herpes zoster - doctors recommend the use of 6 million IU (treatment course - a week) daily, then, if necessary, take 6 million IU in a day for two weeks. It should be combined with the use of interferon alfa2b (as an ointment) every 6 hours;
    solid tumors - adult patients should take 9 million IU as injections intramuscularly or subcutaneously throughout the month every day, maintaining a dosage of 6 million IU three times in 7 days (treatment course - 3 months), children should be administered 3-6 million IU / sq.m according to the same reception scheme. If the effect is positive, the course of treatment can be stretched for a year in a maintenance dosage.
In some cases, treatment regimens may differ. The maximum dosage in this case should not be higher than 3 million IU.

Overdose

In the case of overdose, data on Altevir are not provided.

Interaction

Possible reactions to the combination of Altevir with other drugs are not fully understood. With caution, this drug should be taken with hypnotics and sedatives, as well as those that have a mielosupressive effect, and narcotic analgesics.
If Altevir is used concomitantly with Teofillinum, the concentration of the latter in the blood should be monitored, the dosages may be adjusted.
The combination of the drug with chemotherapeutic antitumor drugs increases the risk of toxic effects.

Storage conditions

Store this medicine at about 2-8 ° C, in no case should not be frozen. The place should not be accessible to children.

Shelf life

Keep the medicine should not be longer than 18 months.

Reviews about Altevir

Reviews about Altevir indicate that many patients are taking the drug quite hard. Very often the forum where this tool is discussed contains reports of the appearance of side effects. Despite this, reviews about Altevir are mostly positive, many patients complain of negative effects, but note the undoubted efficacy of this remedy.